Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3035750rdf:typepubmed:Citationlld:pubmed
pubmed-article:3035750lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:3035750lifeskim:mentionsumls-concept:C0085084lld:lifeskim
pubmed-article:3035750lifeskim:mentionsumls-concept:C0201943lld:lifeskim
pubmed-article:3035750lifeskim:mentionsumls-concept:C0009491lld:lifeskim
pubmed-article:3035750lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:3035750lifeskim:mentionsumls-concept:C2348519lld:lifeskim
pubmed-article:3035750pubmed:issue3lld:pubmed
pubmed-article:3035750pubmed:dateCreated1987-6-26lld:pubmed
pubmed-article:3035750pubmed:abstractTextClinical features such as types of diseases, sex ratio, age of onset, sites of initial involvement, the appearance of bulbar signs, and duration of illness were studied in 52 patients with motor neuron disease (MND) with a special reference to immunoglobulin in cerebrospinal fluid (CSF) and serum. Although MND has been thought to be a degenerative disease of unknown cause, our data suggested there are some immunological abnormalities in this disease. The duration of illness and the abnormalities of CSF immunoglobulins appeared to be correlated with the type of disease and the site of initial involvement. However, whether or not these abnormalities in CSF immunoglobulins are directly related to the pathogenesis of MND remains unclear.lld:pubmed
pubmed-article:3035750pubmed:languageenglld:pubmed
pubmed-article:3035750pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3035750pubmed:citationSubsetIMlld:pubmed
pubmed-article:3035750pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3035750pubmed:statusMEDLINElld:pubmed
pubmed-article:3035750pubmed:monthMarlld:pubmed
pubmed-article:3035750pubmed:issn0040-8727lld:pubmed
pubmed-article:3035750pubmed:authorpubmed-author:NakanoSSlld:pubmed
pubmed-article:3035750pubmed:authorpubmed-author:TakaseSSlld:pubmed
pubmed-article:3035750pubmed:authorpubmed-author:OharaYYlld:pubmed
pubmed-article:3035750pubmed:authorpubmed-author:ItaharaKKlld:pubmed
pubmed-article:3035750pubmed:authorpubmed-author:NomuraHHlld:pubmed
pubmed-article:3035750pubmed:authorpubmed-author:KogureKKlld:pubmed
pubmed-article:3035750pubmed:authorpubmed-author:OkitaNNlld:pubmed
pubmed-article:3035750pubmed:issnTypePrintlld:pubmed
pubmed-article:3035750pubmed:volume151lld:pubmed
pubmed-article:3035750pubmed:ownerNLMlld:pubmed
pubmed-article:3035750pubmed:authorsCompleteYlld:pubmed
pubmed-article:3035750pubmed:pagination323-31lld:pubmed
pubmed-article:3035750pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:3035750pubmed:meshHeadingpubmed-meshheading:3035750-...lld:pubmed
pubmed-article:3035750pubmed:meshHeadingpubmed-meshheading:3035750-...lld:pubmed
pubmed-article:3035750pubmed:meshHeadingpubmed-meshheading:3035750-...lld:pubmed
pubmed-article:3035750pubmed:meshHeadingpubmed-meshheading:3035750-...lld:pubmed
pubmed-article:3035750pubmed:meshHeadingpubmed-meshheading:3035750-...lld:pubmed
pubmed-article:3035750pubmed:meshHeadingpubmed-meshheading:3035750-...lld:pubmed
pubmed-article:3035750pubmed:meshHeadingpubmed-meshheading:3035750-...lld:pubmed
pubmed-article:3035750pubmed:meshHeadingpubmed-meshheading:3035750-...lld:pubmed
pubmed-article:3035750pubmed:meshHeadingpubmed-meshheading:3035750-...lld:pubmed
pubmed-article:3035750pubmed:meshHeadingpubmed-meshheading:3035750-...lld:pubmed
pubmed-article:3035750pubmed:meshHeadingpubmed-meshheading:3035750-...lld:pubmed
pubmed-article:3035750pubmed:meshHeadingpubmed-meshheading:3035750-...lld:pubmed
pubmed-article:3035750pubmed:year1987lld:pubmed
pubmed-article:3035750pubmed:articleTitleComparative studies on clinical features and CSF proteins of motor neuron disease patients.lld:pubmed
pubmed-article:3035750pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3035750pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:3035750pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed